Lynkuet (Elinzanetant): A New Nonhormonal Treatment for Menopausal Hot Flashes and Sleep Disturbances

Lynkuet (elinzanetant) is a new nonhormonal medicine taken by mouth to help manage moderate to severe hot flashes linked to menopause. Hot flashes, also called vasomotor symptoms (VMS), can cause sudden feelings of heat, sweating,… Read more

FDA Approves At-Home Once-Weekly Leqembi Injection as Maintenance Therapy for Early Alzheimer’s Disease

Leqembi (lecanemab-irmb) is a prescription medicine approved to treat early stages of Alzheimer’s disease, such as mild cognitive impairment or mild dementia. The recent FDA approval of Leqembi IQLIK (pronounced “I Click”) introduces a once-weekly,… Read more

FDA Approves Rasonque for Advanced Pancreatic Cancer

The FDA has approved Rasonque (daraxonrasib) to treat adults with advanced pancreatic cancer. The drug is for people with pancreatic adenocarcinoma that has spread to other parts of the body. It is used when patients… Read more

FDA Approves Rybrevant Faspro: A Time-Saving Under-the-Skin Injection for Use in Combination With Lazcluze for EGFR-Mutated Lung Cancer

Rybrevant Faspro is a new under-the-skin (subcutaneous, or SC) injection form of the anticancer medicine Rybrevant (amivantamab). The FDA has now approved it in combination with another medicine called Lazcluze (lazertinib) as a first-line treatment for… Read more

Enhertu Plus Pertuzumab: New First-Line Option for Advanced HER2-Positive Metastatic Breast Cancer

Enhertu (fam-trastuzumab deruxtecan-nxki) is a type of targeted cancer treatment called an antibody-drug conjugate. The FDA has approved it in combination with another medicine, pertuzumab, as the first-line treatment for adults with HER2-positive breast cancer… Read more

FDA Approves Breyanzi: First and Only CAR T-Cell Therapy for Relapsed or Refractory Marginal Zone Lymphoma

  Breyanzi(lisocabtagene maraleucel) is a type of personalized cancer treatment called chimeric antigen receptor (CAR) T-cell therapy, which uses your modified T cells (white blood cells that help protect you from illness) to fight cancer. The… Read more

Cavhanza (Nilotinib): FDA Approves Orally Disintegrating Tablet for Adults With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Cavhanza (nilotinib) is a new FDA-approved orally disintegrating tablet (ODT) formulation of nilotinib, a prescription medicine used to treat a type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). The FDA has… Read more

FDA Approves Keytruda and Keytruda Qlex to Treat Bladder Cancer Before and After Surgery

The FDA approved two options of medicine for adults with a certain type of bladder cancer. This cancer is called muscle-invasive bladder cancer. It means the cancer has grown deep into the main muscle wall… Read more

Are Wet Dreams Normal and Healthy?

Are ‘Wet Dreams’ Normal and Healthy? Nocturnal emissions are a natural part of growing up and nothing to worry about  available to view online.   In fact, some areas may be noticeably up and active.… Read more

Calquence Plus Venclexta: FDA Approves First All‑Oral Fixed‑Duration Regimen for Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The FDA has approved a new combination treatment for adults with certain cancers of the blood and lymphatic system. The targeted regimen combines Calquence (acalabrutinib) tablets with Venclexta (venetoclax) for adults with previously untreated chronic lymphocytic… Read more